Evidence map›Paper›PMID 30013082›Full record

ArticleScientific reports2018

A spike-modified Middle East respiratory syndrome coronavirus (MERS-CoV) infectious clone elicits mild respiratory disease in infected rhesus macaques.

Adam S Cockrell, Joshua C Johnson, Ian N Moore, David X Liu, Kevin W Bock, Madeline G Douglas, Rachel L Graham, Jeffrey Solomon, Lisa Torzewski, Christopher Bartos and 3 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
2.0field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Animal Models of COVID-19: Nonhuman Primates.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Histopathologic Evaluation and Scoring of Viral Lung Infection.Methods in molecular biology (Clifton, N.J.) · 2020
    Review
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Adam S CockrellDepartment of Epidemiology, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina, 27599, USA. adam_cockrell@unc.edu.
Joshua C JohnsonIntegrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 8200 Research Plaza, Frederick, Maryland, 21702, USA.ORCID 0000-0002-5677-3841
Ian N MooreInfectious Disease Pathogenesis Section, Comparative Medicine Branch, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20892, USA.
David X LiuIntegrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 8200 Research Plaza, Frederick, Maryland, 21702, USA.
Kevin W BockInfectious Disease Pathogenesis Section, Comparative Medicine Branch, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, 20892, USA.ORCID 0000-0001-9454-0937
Madeline G DouglasDepartment of Epidemiology, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina, 27599, USA.
Rachel L GrahamDepartment of Epidemiology, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina, 27599, USA.
Jeffrey SolomonClinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, Maryland, 21702, USA.
Lisa TorzewskiIntegrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 8200 Research Plaza, Frederick, Maryland, 21702, USA.
Christopher BartosIntegrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 8200 Research Plaza, Frederick, Maryland, 21702, USA.
Randy HartIntegrated Research Facility, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 8200 Research Plaza, Frederick, Maryland, 21702, USA.
Ralph S BaricDepartment of Epidemiology, University of North Carolina-Chapel Hill, Chapel Hill, North Carolina, 27599, USA. rbaric@email.unc.edu.
Reed F JohnsonEmerging Viral Pathogens Section, Laboratory of Immunoregulation, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 8200 Research Plaza, Frederick, Maryland, 21702, USA. johnsonreed@niaid.nih.gov.
National Institutes of Health · USUniversity of North Carolina at Chapel Hill · USLeidos (United States) · US

Funding

Translational CoreU19AI109761 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BARIC, RALPH S · 2014 to 2018
$32.6M
Pathogenesis and countermeasures of poxviruses, hemorrhagic fever viruses, MERSZIAAI001025 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI JOHNSON, REED · 2009 to 2018
$14.1M
CCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001ENIAID NIH HHS HHSN272200700016INIAID NIH HHS HHSN272201000019INIAID NIH HHS U19 AI109761U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (NIAID) AI109761
6 · The paper itself

Abstract

The recurrence of new human cases of Middle East respiratory syndrome coronavirus (MERS-CoV) underscores the need for effective therapeutic countermeasures. Nonhuman primate models are considered the gold standard for preclinical evaluation of therapeutic countermeasures. However, MERS-CoV-induced severe respiratory disease in humans is associated with high viral loads in the lower respiratory tract, which may be difficult to achieve in nonhuman primate models. Considering this limitation, we wanted to ascertain the effectiveness of using a MERS-CoV infectious clone (icMERS-0) previously shown to replicate to higher titers than the wild-type EMC 2012 strain. We observed respiratory disease resulting from exposure to the icMERS-0 strain as measured by CT in rhesus monkeys with concomitant detection of virus antigen by immunohistochemistry. Overall, respiratory disease was mild and transient, resolving by day 30 post-infection. Although pulmonary disease was mild, these results demonstrate for the first time the utility of CT imaging to measure disease elicited by a MERS-CoV infectious clone system in nonhuman primate models.

Indexed as

AnimalsCoronavirus InfectionsDisease Models, AnimalHumansImage Processing, Computer-AssistedLungMacaca mulattaMiddle East Respiratory Syndrome CoronavirusRNA, ViralSeverity of Illness IndexTomography, X-Ray ComputedViral LoadVirus ReplicationRNA, Viral

Identifiers

PMID30013082
PMCPMC6048037
OpenAlexW2830624938

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.